Figure 2 | Laboratory Investigation

Figure 2

From: Differential Expression of β-Galactoside α2,6 Sialyltransferase and Sialoglycans in Normal and Cirrhotic Liver and Hepatocellular Carcinoma

Figure 2

Immunohistology of ST6Gal I and sialoglycans in HCCs and normal and cirrhotic liver. HuH7 cell line tumor cells are positive for ST6Gal I (A), for CD22Rg (B), and SnRg (C) in the Golgi region. Some tumor cells express ligands for CD22 and sialoadhesin in the cytoplasm and at the plasma membrane. D, In normal liver, hepatocytes are positive for ST6Gal I only in the Golgi region. Kupffer cells and endothelial cells are negative for ST6Gal.I. E, In liver cirrhosis, hepatocytes are positive for ST6Gal I in the Golgi region, similar to normal liver. F, In well-differentiated HCC, tumor cells express ST6Gal I in the Golgi region and cytoplasm. Some tumor cells are negative for ST6Gal I. G, In glandular formal HCC, tumor cells express ST6Gal I in the Golgi region. H, In poorly differentiated HCC, most tumor cells lose ST6Gal I. Only a few tumor cells express ST6Gal I in the cytoplasm. I, In cholangiocarcinoma, most tumor cells are negative for ST6Gal I. Hepatocytes (arrow) are positive ST6Gal I. J, In normal liver, ligands for CD22 are present along the bile canaliculi (small arrows) in hepatocytes. In Kupffer cells (big and long arrows) and endothelium (big and short arrows), CD22 ligands are present in cytoplasm. K, In HCC, tumor cells strongly express CD22 ligands in cytoplasm and at the plasma membrane. L, In cholangiocarcinoma, tumor cells strongly express CD22 ligands in cytoplasm and at the plasma membrane.

Back to article page